Early Clinical Experience with Molnupiravir for Mild to Moderate Breakthrough COVID-19 among Fully Vaccinated Patients at Risk for Disease Progression

Information on the efficacy and safety of molnupiravir in daily clinical practice is very scarce. We aimed to describe the clinical characteristics and outcomes of fully vaccinated patients with mild to moderate breakthrough COVID-19 treated with molnupiravir between January 2022 and February 2022....

Descripción completa

Detalles Bibliográficos
Autores principales: Vena, Antonio, Traman, Luca, Bavastro, Martina, Limongelli, Alessandro, Dentone, Chiara, Magnè, Federica, Giacobbe, Daniele Roberto, Mikulska, Malgorzata, Taramasso, Lucia, Di Biagio, Antonio, Bassetti, Matteo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9318911/
https://www.ncbi.nlm.nih.gov/pubmed/35891305
http://dx.doi.org/10.3390/vaccines10071141

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9318911/
https://www.ncbi.nlm.nih.gov/pubmed/35891305
http://dx.doi.org/10.3390/vaccines10071141

Ejemplares similares